1. Microglia-astrocyte crosstalk in the amyloid plaque niche of an Alzheimer's disease mouse model, as revealed by spatial transcriptomics.
- Author
-
Mallach A, Zielonka M, van Lieshout V, An Y, Khoo JH, Vanheusden M, Chen WT, Moechars D, Arancibia-Carcamo IL, Fiers M, and De Strooper B
- Subjects
- Animals, Mice, Hippocampus metabolism, Hippocampus pathology, Mice, Transgenic, Cell Communication, Signal Transduction, Neurons metabolism, Neurons pathology, Male, Alzheimer Disease metabolism, Alzheimer Disease pathology, Alzheimer Disease genetics, Microglia metabolism, Microglia pathology, Astrocytes metabolism, Astrocytes pathology, Plaque, Amyloid metabolism, Plaque, Amyloid pathology, Disease Models, Animal, Transcriptome genetics
- Abstract
The amyloid plaque niche is a pivotal hallmark of Alzheimer's disease (AD). Here, we employ two high-resolution spatial transcriptomics (ST) platforms, CosMx and Spatial Enhanced Resolution Omics-sequencing (Stereo-seq), to characterize the transcriptomic alterations, cellular compositions, and signaling perturbations in the amyloid plaque niche in an AD mouse model. We discover heterogeneity in the cellular composition of plaque niches, marked by an increase in microglial accumulation. We profile the transcriptomic alterations of glial cells in the vicinity of plaques and conclude that the microglial response to plaques is consistent across different brain regions, while the astrocytic response is more heterogeneous. Meanwhile, as the microglial density of plaque niches increases, astrocytes acquire a more neurotoxic phenotype and play a key role in inducing GABAergic signaling and decreasing glutamatergic signaling in hippocampal neurons. We thus show that the accumulation of microglia around hippocampal plaques disrupts astrocytic signaling, in turn inducing an imbalance in neuronal synaptic signaling., Competing Interests: Declaration of interests B.D.S. has been a consultant for Eli Lilly, Biogen, Janssen Pharmaceutica, Eisai, AbbVie, and other companies and is now consultant to Muna Therapeutics. B.D.S. is a scientific founder of Augustine Therapeutics and a scientific founder and stockholder of Muna Therapeutics. M.F. is a consultant to Muna Therapeutics. Y.A. and J.H.K. are employees of BGI Research, and M.V. and W.T.-C. are employed by Muna Therapeutics. W.T.-C. is also a stockholder of Muna Therapeutics., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF